VALPROATE SODIUM
Manufacturer: Hikma Pharmaceuticals USA Inc.
Score: 148.0
Valproate Sodium Injection is used for the treatment of epilepsy, including complex partial seizures, simple and complex absence seizures, and as an adjunctive therapy in patients with multiple seizure types that include absence seizures. It is also used in the prophylaxis of migraine headaches. However, its use is contraindicated in pregnancy due to the risk of birth defects and other serious adverse effects. The drug has several important safety warnings, including the risk of hepatotoxicity, teratogenicity, and pancreatitis. Dosing recommendations vary based on the condition being treated and the age of the patient, with careful monitoring required for dose adjustments and potential interactions with other medications. Special considerations are needed for use in pregnancy, nursing mothers, pediatric patients, and geriatric patients due to increased risks of adverse effects.
Valproate Sodium Injection can cause serious and potentially life-threatening liver damage, birth defects, and pancreatitis.
Dose adjustments may be necessary based on patient response, serum concentrations, and potential interactions with other medications.
10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day
10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day